Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-24,662Price:--
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,662Price:$77.24
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:24,662Price:$1.30
-
Mar 15, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,347Price:$71.61
-
Mar 15, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,347Price:$29.91
-
Mar 15, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,347Price:--
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-16,976Price:--
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-13,000Price:--
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16,976Price:$69.70
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:16,976Price:$25.53
Filings by filing date
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-24,662Price:--
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,662Price:$77.24
-
Apr 01, 2024 (filed on Apr 01, 2024)Insider Name:Jacobson Mark L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:24,662Price:$1.30
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-16,976Price:--
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-13,000Price:--
-
Mar 15, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,347Price:$71.61
-
Mar 15, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,347Price:$29.91
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16,976Price:$69.70
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:16,976Price:$25.53
-
Mar 14, 2024 (filed on Mar 15, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,000Price:$69.70
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One World Trade Center, 22Nd Floor NEW YORK NY 10007 |
Tel: | N/A |
Website: | https://www.axsome.com |
IR: | See website |
Key People | ||
Herriot Tabuteau Chairman of the Board, President, Chief Executive Officer, Founder | Nick Pizzie Chief Financial Officer | Mark L. Jacobson Chief Operating Officer |
Lori Englebert Executive Vice President - Commercial and Business Development | Hunter Murdock General Counsel |
Business Overview |
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. |
Financial Overview |
For the fiscal year ended 31 December 2023, Axsome Therapeutics Inc revenues increased from $50M to $270.6M. Net loss increased 28% to $239.2M. Revenues reflect Product sales, net increase from $50M to $202.5M. Higher net loss reflects Novel therapies for management of CNS disorders segment loss increase of 29% to $231.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$4.60 to -$5.27. |
Employees: | 545 as of Feb 13, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,189M as of Dec 31, 2023 |
Annual revenue (TTM): | $270.60M as of Dec 31, 2023 |
EBITDA (TTM): | -$224.99M as of Dec 31, 2023 |
Net annual income (TTM): | -$239.24M as of Dec 31, 2023 |
Free cash flow (TTM): | -$145.66M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 47,374,375 as of Feb 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |